Evidence map›Paper›PMID 29780253›Full record

ArticleOncoTargets and therapy2018

A 5-serum miRNA panel for the early detection of colorectal cancer.

Shaohua Guo, Jiajin Zhang, Baishi Wang, Bingdong Zhang, Xuning Wang, Liang Huang, Hongyi Liu, Baoqing Jia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Role of microRNA in colorectal carcinoma (CRC): a narrative review.Annals of medicine and surgery (2012) · 2024
    Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shaohua GuoChinese PLA Medical School, Beijing, China.
Jiajin ZhangGeneral Surgery Department II, Chinese PLA General Hospital, Beijing, China.
Baishi WangGeneral Surgery Department II, Chinese PLA General Hospital, Beijing, China.
Bingdong ZhangChinese PLA Medical School, Beijing, China.
Xuning WangChinese PLA Medical School, Beijing, China.
Liang HuangChinese PLA Medical School, Beijing, China.
Hongyi LiuGeneral Surgery Department II, Chinese PLA General Hospital, Beijing, China.
Baoqing JiaChinese PLA Medical School, Beijing, China.

Funding

Integration of Evidence-based Alcohol Interventions into HIV CareU01AA020802 · NIAAA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CROPSEY, KAREN L, MUGAVERO, MICHAEL J · 2011 to 2020
$4.2M
NIAAA NIH HHS U01 AA020802
6 · The paper itself

Abstract

objectiveThe study aimed to screen microRNAs (miRNAs) that can be used for the early detection of colorectal cancer (CRC) based on differential expression of miRNA in serum. MATERIALS AND

methodsA three-stage study was designed with a total of 217 CRCs, 168 colorectal adenomas (CRAs), and 190 healthy controls (HCs). A quantitative reverse transcription polymerase chain reaction was performed in three stages. We screened 528 miRNA expression profiles in the sera of 40 patients (CRC n=20, CRA n=10, and HC n=10) for candidate miRNAs, then 210 serum samples (CRC n=90, CRA n=60, and HC n=60) were used for screening of candidate miRNAs. Three hundred and twenty-five independent individual samples (CRC n=107, CRA n=98, and HC n=120) were used to validate the most differentially-expressed miRNAs in the screening stage, and binary logistic regression was used in the validation stage. A receiver operating characteristic curve was drawn to evaluate the diagnostic accuracy.

resultsA 5-serum miRNA panel (miRNA-1246, miRNA-202-3p, miRNA-21-3p, miRNA-1229-3p, and miRNA-532-3p) effectively distinguished CRCs from HCs with 91.6% sensitivity and 91.7% specificity. The area under the curve (AUC) was 0.960 (95% confidence interval [CI]: 0.937-0.983). In addition, the panel also accurately distinguished CRCs from CRAs with 94.4% sensitivity and 84.7% specificity. The AUC was 0.951 (95% CI: 0.922-0.980).

conclusionOur 5-serum miRNA panel accurately distinguished CRCs from CRAs and HCs with high sensitivity and specificity. The 5-serum miRNA panel may be a promising prospect for application as a nonintrusive and inexpensive method for the early detection of CRC.

Indexed as

colorectal adenomacolorectal cancermiRNA

Identifiers

PMID29780253
PMCPMC5951214

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.